Online Program Home
  My Program
CC = Baltimore Convention Center,    H = Hilton Baltimore
* = applied session       ! = JSM meeting theme

Activity Details

CE_08C Sun, 7/30/2017, 8:30 AM - 5:00 PM H-Holiday Ballroom 4
Bayesian and Frequentist Adaptive Methods for Clinical Trials (ADDED FEE) — Professional Development Continuing Education Course
ASA , Section on Bayesian Statistical Science
Clinical trials play a critical role in pharmaceutical drug development. New trial designs often depend on historical data, which, however, may not be accurate for the current study due to changes in study populations, patient heterogeneity, or different medical facilities. As a result, the original plan and study design may need to be adjusted or even altered to accommodate new findings and unexpected interim results. Through carefully thought-out and planned adaptation, the right dose can be identified faster, patients can be treated more effectively, and treatment effects evaluated more efficiently. This one-day short course will introduce various adaptive methods for Phase I to Phase III clinical trials using both, frequentist and Bayesian methods. Accordingly, different types of adaptive designs will be introduced and illustrated with case studies. This includes dose escalation/de-escalation and dose insertion based on observed data, adaptive dose finding studies using optimal designs to allocate new cohorts of patients based on the accumulated evidence, population enrichment designs, early stopping for toxicity, futility, or efficacy using group-sequential designs, blinded and unblinded sample size reestimation as well as adaptive designs for confirmatory trials with treatment or population selection at interim.
Instructor(s): Peter Mueller, UT Austin, Frank Bretz, Novartis AG, Byron Jones, Novartis Pharma
Copyright © American Statistical Association